Log in to save to my catalogue

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_swepub_ki_se_474431

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

Luspatercept is a fusion protein aimed at binding TGF-β family members and reducing SMAD2 and SMAD3 signaling in patients with myelodysplasia with ring sideroblasts. In a randomized trial involving transfusion-dependent patients with lower-risk disease, transfusion independence for 8 weeks or longer occurred in 38% of patients in the luspatercept g...

Alternative Titles

Full title

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_swepub_primary_oai_swepub_ki_se_474431

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_swepub_ki_se_474431

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1908892

How to access this item